MCID: BRN015
MIFTS: 55

Bronchiolo-Alveolar Adenocarcinoma

Categories: Cancer diseases, Respiratory diseases
Data Licensing
For inquiries, contact:

Aliases & Classifications for Bronchiolo-Alveolar Adenocarcinoma

MalaCards integrated aliases for Bronchiolo-Alveolar Adenocarcinoma:

Name: Bronchiolo-Alveolar Adenocarcinoma 11 14
Bronchioloalveolar Carcinoma 11 16
Minimally Invasive Lung Adenocarcinoma 11
Adenocarcinoma, Bronchiolo-Alveolar 43
Bronchioloalveolar Adenocarcinoma 71
Bronchioalveolar Lung Carcinoma 11
Carcinoma Bronchioloalveolar 53

Classifications:



External Ids:

Disease Ontology 11 DOID:4926
MeSH 43 D002282
NCIt 49 C2923
SNOMED-CT 68 307595008
UMLS 71 C0007120

Summaries for Bronchiolo-Alveolar Adenocarcinoma

Disease Ontology: 11 A lung adenocarcinoma characterized by a predominantly lepidic pattern and 5 mm or less invasion in greatest dimension.

MalaCards based summary: Bronchiolo-Alveolar Adenocarcinoma, also known as bronchioloalveolar carcinoma, is related to nonmucinous bronchioloalveolar adenocarcinoma and mucinous bronchioloalveolar adenocarcinoma, and has symptoms including fever, hemoptysis and dyspnea. An important gene associated with Bronchiolo-Alveolar Adenocarcinoma is NKX2-1 (NK2 Homeobox 1), and among its related pathways/superpathways are Endometrial cancer and IL-1 Family Signaling Pathways. The drugs Gefitinib and Immunoglobulins, Intravenous have been mentioned in the context of this disorder. Affiliated tissues include lung, endothelial and lymph node, and related phenotypes are Reduced mammosphere formation and neoplasm

Related Diseases for Bronchiolo-Alveolar Adenocarcinoma

Diseases related to Bronchiolo-Alveolar Adenocarcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 476)
# Related Disease Score Top Affiliating Genes
1 nonmucinous bronchioloalveolar adenocarcinoma 32.6 NKX2-1 KRT20
2 mucinous bronchioloalveolar adenocarcinoma 32.4 NKX2-1 KRT7 KRT20 CDX2
3 exanthem 30.6 KRAS HRAS EGFR
4 small cell cancer of the lung 30.6 NKX2-1 KRT7 KRT20 EGFR CEACAM5
5 benign mesothelioma 30.5 NKX2-1 KRT7 KRT20 CEACAM5
6 peutz-jeghers syndrome 30.5 MUC6 MUC5AC EGFR
7 lymphangitis 30.4 NKX2-1 KRT7 EGFR CEACAM5
8 goblet cell carcinoid 30.4 KRT20 CDH1
9 bronchus cancer 30.4 KRT7 FHIT EGFR CEACAM5
10 small cell carcinoma 30.3 NKX2-1 KRT7 KRT20 EGFR CEACAM5
11 hemangioma 30.3 NKX2-1 KRT7 KRAS EGFR CDH1
12 pulmonary adenocarcinoma in situ 30.3 NKX2-1 KRT7 KRAS HRAS EGFR
13 solid adenocarcinoma with mucin production 30.2 NKX2-1 MUC6 MUC5AC KRT7
14 papillary adenocarcinoma 30.2 NKX2-1 KRT7 KRAS HRAS CEACAM5 CDX2
15 appendix adenocarcinoma 30.2 KRT7 KRT20 KRAS HRAS CEACAM5 CDX2
16 lung benign neoplasm 30.2 NKX2-1 KRT7 KRT20 KRAS HRAS FHIT
17 cystadenocarcinoma 30.2 MUC5AC KRT7 KRAS CEACAM5
18 neuroendocrine tumor 30.1 NKX2-1 KRT20 CDX2 CDH1
19 pleural disease 30.1 MIR32 EGFR CEACAM5
20 adenocarcinoma in situ 30.1 NKX2-1 MUC6 KRT7 KRAS HRAS EGFR
21 lung cancer susceptibility 3 30.0 NKX2-1 MUC5AC MUC4 KRT7 KRT20 KRAS
22 thymoma 30.0 NKX2-1 KRT7 HRAS EGFR
23 mucoepidermoid carcinoma 30.0 MUC5AC MUC4 KRT7 EGFR CDH1
24 mesothelioma, malignant 29.8 NKX2-1 MIR32 KRT7 KRT20 CEACAM5 CDH1
25 rhabdomyosarcoma 29.7 LOX KRT7 KRAS HRAS EGFR CEACAM5
26 mucinous cystadenocarcinoma 29.7 KRT7 KRT20 KRAS HRAS CEACAM5 CDX2
27 mucinous adenocarcinoma 29.7 NKX2-1 MUC6 MUC5AC KRT7 KRT20 KRAS
28 pancreatic adenocarcinoma 29.6 TIMP2 MUC4 KRAS HRAS EGFR
29 large cell carcinoma 29.5 TIMP2 NKX2-1 KRT7 KRT20 KRAS HRAS
30 leukemia, acute myeloid 29.4 MIR30C1 KRAS HRAS EIF4E EGFR CDH1
31 colon adenocarcinoma 29.4 KRT20 KRAS HRAS EIF4E EGFR CEACAM5
32 squamous cell carcinoma 29.3 NKX2-1 KRT7 KRAS HRAS FHIT EIF4E
33 signet ring cell adenocarcinoma 29.2 MUC6 MUC5AC KRT7 KRT20 KRAS HRAS
34 adenocarcinoma 28.9 TIMP2 NKX2-1 MUC5AC MUC4 KRT7 KRT20
35 gastric cancer 28.6 TIMP2 MUC6 MUC5AC MUC4 LOX KRT20
36 lung cancer 28.3 TIMP2 NKX2-1 MUC5AC MUC4 MIR32 MIR30C1
37 pancreatic cancer 28.2 MUC6 MUC5AC MUC4 MIR32 LOX KRT7
38 mixed mucinous and nonmucinous bronchioloalveolar adenocarcinoma 11.3
39 cystic adenomatoid malformation of lung 10.5
40 glass syndrome 10.5
41 bladder signet ring cell adenocarcinoma 10.4 KRT7 CDX2
42 bile duct signet ring cell carcinoma 10.4 KRT7 KRT20
43 endometrial transitional cell carcinoma 10.4 KRT7 KRT20
44 ovary neuroendocrine neoplasm 10.4 KRT7 CDX2
45 nephrogenic adenoma of urinary bladder 10.4 KRT7 KRT20
46 atrophic vulva 10.4 KRT7 KRT20
47 bladder benign neoplasm 10.4 KRT7 KRT20
48 anal canal paget's disease 10.4 KRT7 CDX2
49 lacrimal gland mucoepidermoid carcinoma 10.4 KRT7 KRT20
50 papillary squamous carcinoma 10.4 KRT7 EGFR

Graphical network of the top 20 diseases related to Bronchiolo-Alveolar Adenocarcinoma:



Diseases related to Bronchiolo-Alveolar Adenocarcinoma

Symptoms & Phenotypes for Bronchiolo-Alveolar Adenocarcinoma

UMLS symptoms related to Bronchiolo-Alveolar Adenocarcinoma:


fever; hemoptysis; dyspnea; coughing

GenomeRNAi Phenotypes related to Bronchiolo-Alveolar Adenocarcinoma according to GeneCards Suite gene sharing:

25
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Reduced mammosphere formation GR00396-S 9.28 CDH1 EGFR EIF4E HRAS HYAL2 KRAS

MGI Mouse Phenotypes related to Bronchiolo-Alveolar Adenocarcinoma:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 neoplasm MP:0002006 10 CDH1 CDX2 CEACAM5 EGFR EIF4E FHIT
2 homeostasis/metabolism MP:0005376 9.8 CDH1 CDX2 CEACAM5 EGFR FHIT HRAS
3 no phenotypic analysis MP:0003012 9.7 CDH1 EGFR HRAS HYAL2 KRAS MIR30C1
4 digestive/alimentary MP:0005381 9.32 CDH1 CDX2 CEACAM5 EGFR FHIT HRAS

Drugs & Therapeutics for Bronchiolo-Alveolar Adenocarcinoma

Drugs for Bronchiolo-Alveolar Adenocarcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 49)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Gefitinib Approved, Investigational Phase 3 184475-35-2 123631
2 Immunoglobulins, Intravenous Phase 2, Phase 3
3 Immunoglobulins Phase 2, Phase 3
4 Antibodies, Monoclonal Phase 2, Phase 3
5 Antibodies Phase 2, Phase 3
6 Immunologic Factors Phase 2, Phase 3
7 Mitogens Phase 3
8
Erlotinib Approved, Investigational Phase 2 183319-69-9, 183321-74-6 176870
9
Cisplatin Approved Phase 2 15663-27-1 2767 5702198 441203
10
Docetaxel Approved, Investigational Phase 2 114977-28-5 148124
11
Cetuximab Approved Phase 2 205923-56-4
12
Ipilimumab Approved Phase 2 477202-00-9
13
Metformin Approved Phase 2 1115-70-4, 657-24-9 4091
14
Nivolumab Approved Phase 2 946414-94-4
15
Lenograstim Approved, Investigational Phase 2 135968-09-1
16
Picropodophyllin Approved, Investigational Phase 2 518-28-5, 477-47-4 10607 72435
17
Bevacizumab Approved, Investigational Phase 2 216974-75-3 135329020
18
Lapatinib Approved, Investigational Phase 2 231277-92-2, 388082-78-8 208908
19
Bortezomib Approved, Investigational Phase 2 179324-69-7 387447 93860
20
Levoleucovorin Approved, Experimental, Investigational Phase 2 68538-85-2, 58-05-9, 73951-54-9 149436 6006
21
Pemetrexed Approved, Investigational Phase 2 150399-23-8, 137281-23-3 60843 446556 135565230
22
Paclitaxel Approved, Vet_approved Phase 2 33069-62-4 36314
23
Carboplatin Approved Phase 2 41575-94-4 10339178 38904
24
Glutamic acid Approved, Nutraceutical Phase 2 56-86-0 33032
25
D-Tyrosine Approved, Experimental, Investigational, Nutraceutical Phase 2 133585-56-5, 60-18-4, 556-02-5 1153 6057
26
Folic acid Approved, Nutraceutical, Vet_approved Phase 2 59-30-3 6037
27
Veliparib Investigational Phase 1, Phase 2 912444-00-9 11960529
28 Protein Kinase Inhibitors Phase 2
29 Hypoglycemic Agents Phase 2
30 Immune Checkpoint Inhibitors Phase 2
31 Adjuvants, Immunologic Phase 2
32 Immunoglobulin G Phase 2
33 Keratolytic Agents Phase 2
34 Dermatologic Agents Phase 2
35 Endothelial Growth Factors Phase 2
36 Poly(ADP-ribose) Polymerase Inhibitors Phase 1, Phase 2
37 Angiogenesis Inhibitors Phase 2
38 Antineoplastic Agents, Immunological Phase 2
39 Vaccines Phase 2
40 Folic Acid Antagonists Phase 2
41 Folate Phase 2
42 Vitamin B9 Phase 2
43 Vitamin B Complex Phase 2
44 Albumin-Bound Paclitaxel Phase 2
45 Antimitotic Agents Phase 2
46 Tubulin Modulators Phase 2
47
Etoposide Approved Phase 1 33419-42-0 36462
48 Soy Bean Phase 1
49
Etoposide phosphate Phase 1 16760419

Interventional clinical trials:

(show all 31)
# Name Status NCT ID Phase Drugs
1 A Phase III Trial of Cisplatin/Etoposide/Radiotherapy With Consolidation Docetaxel Followed by Maintenance Therapy With ZD1839 (NSC-715055) or Placebo in Patients With Inoperable Locally Advanced Stage III Non-Small Cell Lung Cancer Completed NCT00020709 Phase 3 cisplatin;docetaxel;etoposide;gefitinib
2 Randomized Phase II/III Trial of Paclitaxel Plus Carboplatin With or Without Bevacizumab (NSC #704865) in Patients With Advanced Nonsquamous NSCLC Completed NCT00021060 Phase 2, Phase 3 paclitaxel;carboplatin
3 A PHASE III STUDY OF ADJUVANT CHEMOTHERAPY AFTER RESECTION FOR PATIENTS WITH T2N0 STAGE I NON-SMALL CELL CARCINOMA OF THE LUNG Completed NCT00002852 Phase 3 paclitaxel;carboplatin
4 A Phase III Prospective Randomized, Double-Blind, Placebo-Controlled Trial of the Epidermal Growth Factor Receptor Antagonist, ZD1839 (IRESSA) in Completely Resected Primary Stage IB, II and IIIA Non-Small Cell Lung Cancer Completed NCT00049543 Phase 3 gefitinib
5 Prospective Evaluation of Small Molecule EGFR-1 Tyrosine Kinase Inhibition as a First-Line Treatment in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) Harbouring a Mutant EGFR Gene Unknown status NCT00339586 Phase 2 Erlotinib
6 A Phase II Trial of the Combination of OSI-774 (ERLOTINIB; NSC-718781) and Bevacizumab (Rhumab VEGF; NSC-704865) in Stage IIIB and IV Bronchioloalveolar Carcinoma (BAC) and Adenocarcinoma With BAC Features (ADENOBAC) Completed NCT00436332 Phase 2 erlotinib hydrochloride
7 Phase II Trial of Chronic Oral ZD1839 (Iressa®) (NSC-715055) in Both Previously-Untreated and Previously-Treated Patients With Selected Stage IIIB and IV Bronchioloalveolar Carcinoma (BAC) Completed NCT00029003 Phase 2 gefitinib
8 Phase II Trial of Paclitaxel by 96-Hour Infusion in Stage IIIB and IV Bronchioloalveolar Carcinoma (BAC) Completed NCT00002969 Phase 2 paclitaxel
9 A Randomized Phase II Study of Schedule-Modulated Concomitant Pemetrexed (Alimta) and Erlotinib (Tarceva) vs Single Agent Pemetrexed (Alimta®) in Patients With Progressive or Recurrent Non-small Cell Lung Cancer (NSCLC) Completed NCT00950365 Phase 2 Erlotinib Hydrochloride;Pemetrexed Disodium
10 Phase II Trial of the Akt Inhibitor MK-2206 Plus Erlotinib (OSI-774) in Patients With Advanced Non-small Cell Lung Cancer Who Have Progressed After Previous Response (Including Stable Disease) With Erlotinib Therapy Completed NCT01294306 Phase 2 Akt Inhibitor MK2206;Erlotinib Hydrochloride
11 A Phase II Randomized Study of OSI-774 (Erlotinib) (NSC #718781) With or Without Carboplatin/Paclitaxel in Patients With Previously Untreated Adenocarcinoma of the Lung Who Never Smoked or Were Former Light Smokers Completed NCT00126581 Phase 2 Carboplatin;Erlotinib;Erlotinib Hydrochloride;Paclitaxel
12 Effect of an Early Therapeutic Permutation on the Tumoral Control of Patients Receiving in First Line a Specific Inhibitor of Tyrosin Kinase of EGFR (Erlotinib) or a Taxan-based Chemotherapy for the Treatment of Not Resecable Adenocarcinoma With Bronchiolo-alveolar. Completed NCT00384826 Phase 2 erlotinib;paclitaxel + carboplatine
13 Phase II Study of Bortezomib (PS-341) for Patients With Advanced Bronchiolo-Alveolar Carcinoma (BAC) or Adenocarcinoma With BAC Features Completed NCT00118144 Phase 2 bortezomib
14 A Phase II Trial of Combination Carboplatin, Paclitaxel, Cetuximab and Bevacizumab (NSC-704865) Followed By Cetuximab and Bevacizumab in Patients With Advanced Non-Small Cell Lung Cancer Completed NCT00368992 Phase 2 paclitaxel
15 ZD1839 (NSC #715055, IND #61187) With Induction Paclitaxel And Carboplatin Followed By Either Radiation Or Concomitant Radiation With Weekly Paclitaxel And Carboplatin In Stage III Non-Small Cell Lung Cancer, A Phase II Study Completed NCT00040794 Phase 2 paclitaxel;carboplatin;gefitinib
16 Phase II Study of Sequential Dose-Dense Chemotherapy and Dose-Intense Erlotinib for the Initial Treatment of Advanced Non-Small Cell Lung Cancer Completed NCT01557959 Phase 2 cisplatin;erlotinib hydrochloride;docetaxel
17 DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors Recruiting NCT02834013 Phase 2
18 Randomized Phase II Trial of Concurrent Chemoradiotherapy +/- Metformin HCL in Locally Advanced NSCLC Active, not recruiting NCT02186847 Phase 2 Carboplatin;Metformin;Paclitaxel
19 Phase II Randomized Clinical Trials Comparing Immunotherapy Plus Stereotactic Ablative Radiotherapy (I-SABR) Versus SABR Alone for Stage I, Selected Stage IIa, or Isolated Lung Parenchymal Recurrent Non-Small Cell Lung Cancer: I-SABR Active, not recruiting NCT03110978 Phase 2
20 A Pilot Trial of Cisplatin/Etoposide/Radiotherapy Followed by Consolidation Docetaxel and the Addition of Bevacizumab (NSC-704865) in Three Cohorts of Patients With Inoperable Locally Advanced Stage III Non-small Cell Lung Cancer Active, not recruiting NCT00334815 Phase 2 Cisplatin;Docetaxel;Etoposide
21 A Dose Finding Study Followed by Phase II Randomized, Placebo-Controlled Study of Veliparib (ABT-888) Added to Chemoradiotherapy With Carboplatin and Paclitaxel for Unresectable Stage III Non-small Cell Lung Cancer (NSCLC), (NCI Study Number 8811) Active, not recruiting NCT01386385 Phase 1, Phase 2 Carboplatin;Paclitaxel;Veliparib
22 A Phase 2 Multicenter Trial Comparing Two Schedules of GW572016 as First or Second Line Monotherapy in Subjects With Advanced or Metastatic Non-Small Cell Lung Cancer With Either Bronchioloalveolar Carcinoma or No Smoking History Terminated NCT00073008 Phase 2 GW572016 (lapatinib)
23 A Multicenter, Open-Label, Phase 2 Study of VELCADE (Bortezomib) for Injection in Previously Treated Patients With Stage IIIB and IV Bronchioloalveolar Carcinoma and Adenocarcinoma With Bronchioloalveolar Features Terminated NCT00117351 Phase 2 VELCADE
24 Phase II Trial of CG8123, an Autologous Cancer Vaccine (GVAX), in Patients With Selected Stage IIIB and IV Bronchioloalveolar Carcinoma (BAC) Terminated NCT00074295 Phase 2
25 Phase II Trial of Pemetrexed in Patients With Selected Stage IIIB and IV Bronchioloalveolar Carcinoma (BAC) Terminated NCT00265785 Phase 2 pemetrexed
26 A Phase II Randomized Trial of Paclitaxel, Carboplatin, Bevacizumab With or Without IMC-A12 in Patients With Advanced Non-squamous, Non-small Cell Lung Cancer Terminated NCT00955305 Phase 2 Carboplatin;Paclitaxel
27 Phase I Study of Thoracic Radiotherapy and Concurrent Chemotherapy With Soy Isoflavones in Stage III NSCLC (Non-Small Cell Lung Cancer) Patients Completed NCT01958372 Phase 1 cisplatin;etoposide;pemetrexed disodium
28 A Safety and Feasibility Study of Bevacizumab With Paclitaxel, Carboplatin and Chest Radiotherapy in Patients With Locally Advanced Non-Small Lung Cancer Terminated NCT00369551 Phase 1 paclitaxel;carboplatin
29 A Phase I Study Of OSI-774 (NSC #718781)-Based Multimodality Therapy For Inoperable Stage III Non Small Cell Lung Cancer Terminated NCT00042835 Phase 1 cisplatin;etoposide;erlotinib hydrochloride;docetaxel;paclitaxel;carboplatin
30 Prospective Cohort Study of Telomere Biology Among Patients With Early Adenocarcinoma of the Lung Unknown status NCT02239432
31 The PIONEER Initiative: Precision Insights On N-of-1 Effectiveness Research. Tissue Ownership by the Individual With the Return of Actionable Information to the Individual Patient and Physician (Precision Oncology) Recruiting NCT03896958

Search NIH Clinical Center for Bronchiolo-Alveolar Adenocarcinoma

Cochrane evidence based reviews: adenocarcinoma, bronchiolo-alveolar

Genetic Tests for Bronchiolo-Alveolar Adenocarcinoma

Anatomical Context for Bronchiolo-Alveolar Adenocarcinoma

Organs/tissues related to Bronchiolo-Alveolar Adenocarcinoma:

MalaCards : Lung, Endothelial, Lymph Node, Thyroid, Adrenal Gland, Fetal Lung, Whole Blood

Publications for Bronchiolo-Alveolar Adenocarcinoma

Articles related to Bronchiolo-Alveolar Adenocarcinoma:

(show top 50) (show all 1007)
# Title Authors PMID Year
1
Genetic evolution of epidermal growth factor receptor in adenocarcinoma with a bronchioloalveolar carcinoma component. 53 62
20439191 2010
2
Promoter methylation of glutathione S-transferase pi1 and multidrug resistance gene 1 in bronchioloalveolar carcinoma and its correlation with DNA methyltransferase 1 expression. 53 62
20120028 2010
3
Is the epidermal growth factor receptor status in lung cancers reflected in clinicopathologic features? 53 62
20073607 2010
4
Promoter methylation of glutathione S-transferase pi1 and multidrug resistance gene 1 in bronchioloalveolar carcinoma and its correlation with DNA methyltransferase 1 expression. 53 62
19484794 2009
5
Morphologic features of adenocarcinoma of the lung predictive of response to the epidermal growth factor receptor kinase inhibitors erlotinib and gefitinib. 53 62
19260752 2009
6
Bronchioloalveolar carcinoma presenting as chronic progressive pulmonary infiltrates in a woman with HIV: a diagnosis worth making. 53 62
18978572 2008
7
Long-lasting complete remission with tyrosine kinase inhibitor in bronchioloalveolar carcinoma with a so far unknown EGFR mutation. 53 62
18379371 2008
8
Epidermal growth factor receptor signaling in adenocarcinomas with bronchioloalveolar components. 53 62
18154814 2008
9
Microsatellite and EGFR, HER2 and K-RAS analyses in sclerosing hemangioma of the lung. 53 62
17895751 2007
10
MUC-1 (CA 15-3 antigen) as a highly reliable predictor of response to EGFR inhibitors in patients with bronchioloalveolar carcinoma: an experience on 26 patients. 53 62
18161663 2007
11
[Value of thyroid transcription factor-1 in identification of the prognosis of bronchioloalveolar carcinoma]. 53 62
18036300 2007
12
Epidermal growth factor receptor gene mutations in atypical adenomatous hyperplasias of the lung. 53 62
17618248 2007
13
Mucinous differentiation correlates with absence of EGFR mutation and presence of KRAS mutation in lung adenocarcinomas with bronchioloalveolar features. 53 62
17591931 2007
14
[Comparison of the characteristics in recurrence and metastasis between bronchioloalveolar carcinoma and other lung adenocarcinomas]. 53 62
17626761 2007
15
Distinctive evaluation of nonmucinous and mucinous subtypes of bronchioloalveolar carcinomas in EGFR and K-ras gene-mutation analyses for Japanese lung adenocarcinomas: confirmation of the correlations with histologic subtypes and gene mutations. 53 62
17580276 2007
16
Cytomorphological correlates of epidermal growth factor receptor mutations in lung carcinoma. 53 62
17427221 2007
17
Short-term gefitinib treatment brought about a long-term regression of bronchioloalveolar carcinoma without EGFR gene alterations: a case report. 53 62
18196873 2007
18
Frequent EGFR mutations in noninvasive bronchioloalveolar carcinoma. 53 62
16353158 2006
19
A correlation between EGFR gene mutation status and bronchioloalveolar carcinoma features in Japanese patients with adenocarcinoma. 53 62
16449241 2006
20
Bronchioloalveolar carcinoma of mixed mucinous and nonmucinous type: immunohistochemical studies and mutation analysis of the p53 gene. 53 62
16959434 2006
21
Response to gefitinib in bronchioloalveolar carcinoma in the absence of EGFR mutation. 53 62
16009451 2005
22
Gefitinib inhibits MUC5AC synthesis in mucin-secreting non-small cell lung cancer cells. 53 62
16009452 2005
23
Gene amplification and protein expression of EGFR and HER2 by chromogenic in situ hybridisation and immunohistochemistry in atypical adenomatous hyperplasia and adenocarcinoma of the lung. 53 62
16189154 2005
24
Loss of expression of E-cadherin and beta-catenin is associated with progression of pulmonary adenocarcinoma. 53 62
15660698 2005
25
Cadherin superfamily of adhesion molecules in primary lung cancer. 53 62
15627055 2004
26
Usefulness of Cdx2 in separating mucinous bronchioloalveolar adenocarcinoma of the lung from metastatic mucinous colorectal adenocarcinoma. 53 62
15362373 2004
27
Bronchioloalveolar carcinoma: a model for investigating the biology of epidermal growth factor receptor inhibition. 53 62
15217959 2004
28
Expression of MUC1, MUC2, MUC5AC, and MUC6 in atypical adenomatous hyperplasia, bronchioloalveolar carcinoma, adenocarcinoma with mixed subtypes, and mucinous bronchioloalveolar carcinoma of the lung. 53 62
15151204 2004
29
Differential expression of cytokeratins 7 and 20 and thyroid transcription factor-1 in bronchioloalveolar carcinoma: an immunohistochemical study in fine-needle aspiration biopsy specimens. 53 62
15023039 2004
30
Prognostic significance of thyroid transcription factor-1 expression in both early-stage conventional adenocarcinoma and bronchioloalveolar carcinoma of the lung. 53 62
14745718 2004
31
Epidermal growth factor receptor inhibitors, gefitinib and erlotinib (Tarceva , OSI-774), in the treatment of bronchioloalveolar carcinoma. 53 62
14596689 2003
32
Prognostic significance of E-cadherin and beta-catenin in resected stage I non-small cell lung cancer. 53 62
12965318 2003
33
Hyaluronidase 2 negatively regulates RON receptor tyrosine kinase and mediates transformation of epithelial cells by jaagsiekte sheep retrovirus. 53 62
12676986 2003
34
Expression of eukaryotic initiation factor 4E in atypical adenomatous hyperplasia and adenocarcinoma of the human peripheral lung. 53 62
12374671 2002
35
Expression of cytokeratin 20 in mucinous bronchioloalveolar carcinoma. 53 62
12378517 2002
36
Expression of thyroid transcription factor-1, cytokeratin 7, and cytokeratin 20 in bronchioloalveolar carcinomas: an immunohistochemical evaluation of 67 cases. 53 62
12011259 2002
37
Mucinous bronchioloalveolar carcinomas display a specific pattern of mucin gene expression among primary lung adenocarcinomas. 53 62
11274635 2001
38
Basement membrane patterns, gelatinase A and tissue inhibitor of metalloproteinase-2 expressions, and stromal fibrosis during the development of peripheral lung adenocarcinoma. 53 62
10088553 1999
39
Expression of E-cadherin, alpha-catenin, beta-catenin, and gamma-catenin in bronchioloalveolar carcinoma and conventional pulmonary adenocarcinoma: an immunohistochemical study. 53 62
9831199 1998
40
FHIT and p53 gene abnormalities in bronchioloalveolar carcinomas. Correlations with clinicopathological data and K-ras mutations. 53 62
9614374 1998
41
[Aggressive multifocal extensive cutaneous epithelioid haemagioendothelioma. A case report]. 62
36154733 2022
42
FDG avid solitary pulmonary nodule mimicking lung cancer. 62
35145568 2022
43
Surgery for pre- and minimally invasive lung adenocarcinoma. 62
33485660 2022
44
Surgical Strategies for Pre- and Minimally Invasive Lung Adenocarcinoma 3.0: Lessons Learned From the Optimal Timing of Surgical Intervention. 62
33444769 2022
45
Double-mutant invasive mucinous adenocarcinoma of the lung in a 32-year-old male patient: A case report. 62
35047621 2021
46
Diagnosis-to-surgery interval and survival for different histologies of stage I-IIA lung cancer. 62
34430346 2021
47
Bronchioloalveolar carcinoma arising in congenital pulmonary airway malformation in a neonate. 62
33730423 2021
48
Wolf in sheep's clothes: An uncommon case of pneumonic-type adenocarcinoma. 62
34240042 2021
49
Novel PD-L1 mAb HC16 reveals upregulation of PD-L1 in BAC subtype. 62
33112410 2021
50
MUC5AC Expression in Various Tumor Types and Nonneoplastic Tissue: A Tissue Microarray Study on 10 399 Tissue Samples. 62
34547930 2021

Variations for Bronchiolo-Alveolar Adenocarcinoma

Cosmic variations for Bronchiolo-Alveolar Adenocarcinoma:

8 (show top 50) (show all 35906)
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM88263727 ZRSR2 lung,NS,carcinoma,adenocarcinoma c.937+1G>T p.? 23:15820317-15820317 11
2 COSM95442728 ZMYND10 lung,NS,carcinoma,adenocarcinoma c.128A>G p.N43S 3:50345197-50345197 11
3 COSM85262562 ZMYND10 lung,NS,carcinoma,adenocarcinoma c.622C>T p.R208C 3:50342996-50342996 11
4 COSM85263435 ZMYND10 lung,NS,carcinoma,adenocarcinoma c.128A>G p.N43S 3:50345197-50345197 11
5 COSM95441934 ZMYND10 lung,NS,carcinoma,adenocarcinoma c.599+122C>T p.? 3:50342996-50342996 11
6 COSM143112283 ZMYM2 lung,NS,carcinoma,adenocarcinoma c.94G>A p.G32R 13:19993166-19993166 11
7 COSM101592316 ZMYM2 lung,NS,carcinoma,adenocarcinoma c.94G>A p.G32R 13:19993166-19993166 11
8 COSM101606460 ZMYM2 lung,NS,carcinoma,adenocarcinoma c.95G>A p.G32E 13:19993167-19993167 11
9 COSM101614868 ZMYM2 lung,NS,carcinoma,adenocarcinoma c.369G>C p.E123D 13:19993441-19993441 11
10 COSM101585076 ZMYM2 lung,NS,carcinoma,adenocarcinoma c.95G>A p.G32E 13:19993167-19993167 11
11 COSM101614672 ZMYM2 lung,NS,carcinoma,adenocarcinoma c.94G>A p.G32R 13:19993166-19993166 11
12 COSM143112460 ZMYM2 lung,NS,carcinoma,adenocarcinoma c.369G>C p.E123D 13:19993441-19993441 11
13 COSM143103178 ZMYM2 lung,NS,carcinoma,adenocarcinoma c.95G>A p.G32E 13:19993167-19993167 11
14 COSM101592471 ZMYM2 lung,NS,carcinoma,adenocarcinoma c.369G>C p.E123D 13:19993441-19993441 11
15 COSM102032968 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.-23-7406A>C p.? 16:72958371-72958371 11
16 COSM102040512 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.1439C>A p.S480* 16:72798501-72798501 11
17 COSM102043690 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.8060C>T p.S2687L 16:72787474-72787474 11
18 COSM87286137 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.3340C>G p.R1114G 16:72889839-72889839 11
19 COSM102031099 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.7886C>A p.A2629D 16:72787648-72787648 11
20 COSM149303773 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.3340C>G p.R1114G 16:72889839-72889839 11
21 COSM149318853 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.331G>A p.E111K 16:72959815-72959815 11
22 COSM149318882 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.2680G>T p.D894Y 16:72957466-72957466 11
23 COSM149268808 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.256G>T p.A86S 16:72959890-72959890 11
24 COSM102042371 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.-23-6501G>T p.? 16:72957466-72957466 11
25 COSM102037223 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.-23-7773G>T p.? 16:72958738-72958738 11
26 COSM149260552 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.10961C>T p.S3654L 16:72787315-72787315 11
27 COSM87273791 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.2755G>T p.G919C 16:72950930-72950930 11
28 COSM87274581 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.7769C>G p.S2590C 16:72794913-72794913 11
29 COSM87284855 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.4834G>C p.E1612Q 16:72797848-72797848 11
30 COSM149303017 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.2701G>A p.A901T 16:72957445-72957445 11
31 COSM102022101 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.6240C>G p.F2080L 16:72793700-72793700 11
32 COSM102032971 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.-23-7046G>T p.? 16:72958011-72958011 11
33 COSM87287980 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.2767G>T p.V923L 16:72950918-72950918 11
34 COSM149309579 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.2767G>T p.V923L 16:72950918-72950918 11
35 COSM102028052 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.2928G>C p.Q976H 16:72797012-72797012 11
36 COSM149263533 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.1910G>A p.G637E 16:72958236-72958236 11
37 COSM149322707 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.10802C>T p.S3601L 16:72787474-72787474 11
38 COSM87279299 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.6293C>T p.S2098L 16:72796389-72796389 11
39 COSM149327483 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.1582C>T p.Q528* 16:72958564-72958564 11
40 COSM87274095 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.628G>T p.G210C 16:72959518-72959518 11
41 COSM102037726 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.689G>T p.C230F 16:72889748-72889748 11
42 COSM102022617 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.13G>T p.G5C 16:72950930-72950930 11
43 COSM149265687 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.8982C>G p.F2994L 16:72793700-72793700 11
44 COSM87281915 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.6289T>G p.F2097V 16:72796393-72796393 11
45 COSM149269636 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.7769C>G p.S2590C 16:72794913-72794913 11
46 COSM102047871 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.3243C>G p.I1081M 16:72796697-72796697 11
47 COSM149263422 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.941G>A p.R314Q 16:72959205-72959205 11
48 COSM102041859 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.1021C>T p.P341S 16:72811678-72811678 11
49 COSM87272331 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.941G>A p.R314Q 16:72959205-72959205 11
50 COSM149290601 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.10628C>A p.A3543D 16:72787648-72787648 11

Expression for Bronchiolo-Alveolar Adenocarcinoma

Search GEO for disease gene expression data for Bronchiolo-Alveolar Adenocarcinoma.

Pathways for Bronchiolo-Alveolar Adenocarcinoma

Pathways related to Bronchiolo-Alveolar Adenocarcinoma according to GeneCards Suite gene sharing:

(show all 23)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.53 KRAS HRAS FHIT EGFR CDH1
2
Show member pathways
12.43 MUC5AC KRAS HRAS EIF4E EGFR
3
Show member pathways
12.36 KRAS HRAS EGFR CDH1
4
Show member pathways
12.24 TIMP2 KRAS HRAS EGFR CDH1
5
Show member pathways
12.08 KRAS HRAS EIF4E EGFR
6
Show member pathways
11.96 MUC6 MUC5AC MUC4 KRAS HRAS
7
Show member pathways
11.77 KRAS HRAS EGFR
8 11.72 KRAS HRAS EGFR CDH1
9 11.59 CDH1 EIF4E HRAS
10
Show member pathways
11.56 MUC6 MUC5AC MUC4
11 11.48 NKX2-1 CDX2 CDH1
12 11.46 KRAS HRAS EGFR
13 11.35 CDH1 EGFR HRAS
14 11.27 KRAS HRAS EGFR
15 11.2 KRAS HRAS EGFR
16 11.18 HRAS EGFR CDH1
17 11.12 KRAS HRAS EIF4E EGFR
18 11.06 KRAS HRAS EGFR
19 10.94 KRAS HRAS EGFR
20
Show member pathways
10.86 KRAS HRAS EGFR
21 10.79 HRAS EGFR
22
Show member pathways
10.66 KRAS HRAS
23 10.53 KRAS HRAS EGFR CDH1

GO Terms for Bronchiolo-Alveolar Adenocarcinoma

Cellular components related to Bronchiolo-Alveolar Adenocarcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular matrix GO:0031012 9.28 TIMP2 MUC6 MUC5AC MUC4 LOX

Biological processes related to Bronchiolo-Alveolar Adenocarcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 response to hormone GO:0009725 9.02 TIMP2 NKX2-1 LOX

Sources for Bronchiolo-Alveolar Adenocarcinoma

2 CDC
6 CNVD
8 Cosmic
9 dbSNP
10 DGIdb
16 EFO
17 ExPASy
18 FMA
19 GARD
27 GO
28 GTR
29 HMDB
30 HPO
31 ICD10
32 ICD10 via Orphanet
33 ICD11
34 ICD9CM
35 IUPHAR
36 LifeMap
38 LOVD
40 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
52 NINDS
53 Novoseek
55 ODiseA
56 OMIM via Orphanet
57 OMIM® (Updated 08-Dec-2022)
61 PubChem
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....